![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Indivior Presents Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot
Indivior Presents Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot
August 17, 2016
Indivior provided positive top-line results of the pivotal Phase 3 clinical trial of investigational drug, RBP-6000 buprenorphine monthly depot, for the treatment of opioid use disorder to be used in conjunction with counseling and psychosocial support.
RBP-6000 is a subcutaneous long-acting monthly depot injection that delivers a sustained-release formulation of buprenorphine.
The primary objective of this study was to assess the efficacy of monthly SC injections of RBP-6000.
The drug has yet to receive FDA market approval.
Upcoming Events
-
21Oct